Additionally, global collaboration is required in virus surveillance to monitor for potential new variants and to increase the resilience of efforts against the evolution of the SARS-CoV-2 virus. This is important not only now, but also to ensure that the world is prepared for any future pandemics. As the first global pharmaceutical company to have allied with COVAX, we at AstraZeneca are proud of the progress that has been made so far.
Significant milestone reached as 100 countries receive vaccine through COVAX
Authorization can be conditional or emergency use.
To learn more about your local status, please reach out to the local approval authority for specific details.
To overcome the core challenges of inequity experienced during previous pandemics, the World Health Organization (WHO), in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, built the COVAX Facility to enable access to pandemic vaccines for people around the world regardless of income level.1
COVAX is one of four pillars of the Access to COVID-19 Tools (ACT) Accelerator, which was launched in April 2020. Through the collaboration of governments, global health organisations, manufacturers, scientists, private sector, civil society and philanthropic organisations, ACT Accelerator aims to accelerate the development, production and equitable access to COVID-19 diagnostics, treatments and vaccines, ensuring that people in all corners of the world are able to benefit from these tools regardless of their economic means.2
In addition to providing access to the COVID-19 vaccines through COVAX, the WHO is also supporting low-to-middle-income countries (LMICs) in overcoming regulatory hurdles through the Emergency Use Listing (EUL) procedure. This is the procedure of independent regulatory review of medicines/vaccines by experts, based on available quality, safety, and efficacy data, established with the ultimate aim of expediting the availability of these products to people affected by a public health emergency.
In previous pandemics, such as the H1N1 influenza pandemic, vaccines were made available to low and middle income countries (LMICs) only several months after being available in high-income countries.3 Concerns were raised that, had the pandemic been more severe, LMICs would have suffered an enormous impact and many needless deaths due to lack of access to a vaccine.4
In order to support timely access, AstraZeneca has worked at pace to build more than a dozen parallel regional supply chains and is collaborating with over 20 partners from across 15 countries. Through this network, we plan to assist by supplying multiple regions simultaneously, allowing timely access for LMICs in parallel with meeting other global commitments. Crucially, each of these supply chains is supported by an analytical testing network, which employs stringent processes to ensure the highest quality standards are met consistently across each supply chain.
As we continue to work with governments and partners to support access globally, we are also building solid production infrastructure that can support increased delivery. By leveraging and optimising local manufacturing capabilities wherever possible in our supply chains, and undertaking technology transfers and training, we are increasing our capacity to support sustainable and equitable logistics frameworks for vaccine distribution.
Ensuring fair and equitable access to COVID-19 vaccines across geographies and populations is essential to achieving global recovery from the pandemic. It is important that the vaccines are made available in a convenient and timely manner, but also to ensure that their uptake on the ground is practicable, and that the programmes and related infrastructure are built in such a way as to account for future needs.
1. Gavi. COVAX Facility. https://www.gavi.org/covax-facility. Accessed 26 February 2021.
2. World Health Organization. The Access to COVID-19 Tools (ACT) Accelerator. https://www.who.int/initiatives/act-accelerator. Accessed 26 February 2021.
3. World Health Organization. Report of the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative. 2012.
4. Monto AS, Black S, Plotkin AS, Orenstein WA. Response to the 2009 pandemic: Effect on influenza control in wealthy and poor countries. Vaccine. 2011;29:6427-6431.